Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19
Marie Fisk(University of Cambridge), Joseph Cheriyan(University of Cambridge), Ian B. Wilkinson(Oncotherapeutics (United States)), Peter J. Greasley(AstraZeneca (Sweden)), Phil Ambery(AstraZeneca (Brazil)), Sven Moosmang(Boehringer Ingelheim (Germany)), Magnus Althage(AstraZeneca (Sweden)), David Jayne(University of Cambridge), Andrew P. Cope(King's College London), Frances Hall(MRC Weatherall Institute of Molecular Medicine), James Galloway(King's College London)
Cited by 20
Related Papers
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
|Arthritis & Rheumatism|2012|6.6k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
|New England Journal of Medicine|2010|1.7k
Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis
|Journal of the American Society of Nephrology|2007|1.1k